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Summary
 
Background 
 
GH may be beneﬁcial in treating patients with
end-stage renal disease (ESRD). However, the efﬁcacy and safety of
GH could be compromised by the potential for accumulation in the
circulation.
 
Objective 
 
The objective was to investigate the pharmacokinetics
and safety of GH treatment in ESRD patients.
 
Design 
 
This was an open, nonrandomized, single-centre parallel-
group study lasting 8–9 days.
 
Subjects 
 
Eleven adult ESRD patients and 10 matched healthy
individuals received recombinant human GH (50 
 
μ
 
g/kg/day for
7 days) by subcutaneous injection; there were two dose reductions
(25%) from Day 5/7. ESRD patients underwent dialysis four times.
 
Measurements 
 
Serum concentrations of GH, insulin-like growth
factor-I (IGF-I), insulin-like growth factor binding protein-I
(IGFBP-I), IGFBP-III and GHBP were measured. The primary end-
point was GH exposure [area-under-the-curve (AUC) calculated
from the 24-h proﬁle] on Days 7–8.
 
Results 
 
GH AUC
 
0–24 h
 
 was greater for patients (387·91  ±
134·13 
 
μ
 
g h/l) than healthy subjects (225·35 ± 59·63 
 
μ
 
g h/l) and the
90% conﬁdence interval (CI) for the estimated patient : healthy
subject ratio (1·40–2·07) was not within the acceptance interval
(0·67–1·50). GH AUC
 
18–24 h
 
 for patients and healthy subjects (3·03 ±
2·71 
 
μ
 
g h/l  and  6·37 ± 4·21 
 
μ
 
g  h/l) returned approximately to
baseline (2·86 ± 3·91 
 
μ
 
g h/l and 1·09 ± 1·43 
 
μ
 
g h/l); terminal half-
life (
 
t
 
1/2,z
 
) was shorter for patients (2·28 ± 00·43 h 
 
vs.
 
 3·23 ± 00·75 h).
No major safety issues were identiﬁed.
 
Conclusions 
 
Results demonstrate a difference between patients
and healthy subjects regarding GH AUC
 
0–24 h
 
. However, GH con-
centrations for both groups were comparable to baseline by 20–
22 h, thus GH was not retained in the circulation of ESRD patients.
(Received 12 January 2007; returned for revision 19 February 2007; 
 
ﬁnally revised 20 April 2007; accepted 18 May 2007)
 
Introduction
 
Patients with end-stage renal disease undergoing haemodialysis
commonly suffer from malnutrition, which represents one of
the main clinical problems for these patients.
 
1
 
 The prevalence of
malnutrition in dialysis patients is reported to range from 30% to
50% or more.
 
2,3
 
 The state of malnutrition and the malnutrition-
induced systemic inﬂammation in patients with end-stage renal
disease (ESRD) have been associated with the increased mortality
and morbidity observed in these patients.
 
4–9
 
 The cause of the poor
nutritional status is multifactorial, and is associated with anorexia
and reduced nutrient intake,
 
3,10,11
 
 metabolic and hormonal
alterations,
 
12
 
 and catabolic effects associated with dialysis.
 
10
 
 Although
as yet unproven, treatment of malnutrition in these patients can
potentially improve clinical outcome and reduce the risk for
morbidity and mortality. Thus, a number of preventive and
therapeutic measures have been used to treat malnutrition in
patients with ESRD, including anabolic hormones such as GH.
The potential beneﬁcial effects of recombinant human GH
(rhGH) in the treatment of patients with ESRD have been demon-
strated both in short-term studies and long-term (up to 6 months)
randomized, controlled trials. Treatment with rhGH has been
shown to reduce protein catabolism,
 
13,14
 
 increase muscle area and
strength,
 
14–18
 
 increase erythropoietin synthesis,
 
19
 
 and to improve
inﬂammation status and quality of life.
 
20
 
 A recent 6-month study
showed a positive effect of GH treatment on lean body mass and
cardiovascular risk factors.
 
21
 
 Furthermore, GH administration is
associated with improvements in several nutritional parameters,
such as increases in serum insulin-like growth factor-I (IGF-I),
 
13,14,22
 
serum albumin
 
14
 
 and transferrin,
 
13
 
 and a reduction in blood urea
nitrogen.
 
13
 
rhGH has become available for the treatment of children with
chronic renal failure and has been shown to be safe and efﬁcacious.
However, the physiological response to exogenous GH treatment in
adults may be different compared to that in children. As GH is
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cleared partly by the kidneys in healthy subjects,
 
23–25
 
 investigation of
a possible inﬂuence of renal impairment on drug elimination would
be relevant.
 
23,25,26
 
 The primary aim of the current trial was thus to
investigate the pharmacokinetic (PK) aspects and safety of treatment
with rhGH (daily subcutaneous injection) in patients with ESRD
compared with those in healthy subjects. A secondary objective
was to investigate the pharmacodynamic (PD) responses to GH
administration and to compare these in patients with ESRD and in
healthy subjects.
 
Subjects and methods
 
Subjects
 
Twenty-two subjects (11 ESRD patients, 11 healthy subjects) were
enrolled in the study and 21 subjects (mean age 51 years, range 24–
66 years) received treatment with rhGH. There was one screening
failure. One healthy subject withdrew consent prior to treatment
and was withdrawn from the study. The study was performed at
APEX Research Centre (Munich, Germany) in accordance with
the Declaration of Helsinki
 
27
 
 and International Conference on
Harmonization Good Clinical Practice
 
28
 
 and was approved by local
Ethics Committee. All subjects gave written informed consent.
Subject demographics are presented in Table 1.
Inclusion criteria for patients were male or female; age 
 
≥
 
 18 years;
and in chronic and stable haemodialysis 3 months prior to enrol-
ment (measure of dialysis efﬁciency Kt/V > 1·2 and/or haemodialysis
performed for 4 h, three times weekly). The healthy control
population was chosen to enable a valid comparison with ESRD
patients. Main exclusion criteria for all subjects were active
malignant disease; diabetes (fasting blood glucose 
 
≥
 
 7·0 mmol/l);
critical illness (need for respiratory or circulatory support);
parathyroid hormone 
 
≥
 
 500 pmol/l; chronic treatment with steroids;
treatment with immunosuppressive agents; active vasculitis; heart
failure (New York Heart Association class III–IV); severe hepatic
disease; and severe chronic systemic inﬂammation.
 
Study design
 
This was an open, nonrandomized, parallel-group study, comprising
eight visits for healthy subjects and nine visits for patients with
ESRD. The following visits were included for all subjects (Fig. 1):
screening visit, baseline visit (Days 0–1), outpatient visits (Days 2–6),
assessment visit (Days 7–8) and a follow-up visit (Days 16–19).
Variable Patients (N = 11) Healthy subjects (N = 10)
Age (years) 51·3 ± 13·5 (24–66) 50·2 ± 12·5 (28–64)
Sex, N (%)
Female 3 (27) 3 (30)
Male 8 (73) 7 (70)
Race, N (%)
White 11 (100) 10 (100)
Height (cm) 176·5 ± 7·0 (163–189) 172·5 ± 6·8 (162–182)
Weight (kg) 77·5 ± 8·3 (62·2–92·1) 78·3 ± 7·5 (63·5–90·8)
BMI (kg/m
2) 25·0 ± 3·2 (20·3–29·2) 26·3 ± 1·8 (22·8–28·8)
Time in present HD treatment (years) 2·1 ± 2·2* (0·3–6·7) N/A
Kt/V 1·4 ± 0·3 (1·2–2·1) N/A
Systolic blood pressure 127·7 ± 34·0 129·5 ± 10·3
Diastolic blood pressure 80·2 ± 9·3 81·3 ± 7·6
Fasting plasma glucose (mmol/l) 4·6 ± 0·5 4·8 ± 0·5
Values are the mean ± SD (range), except for sex and race, N (%).
 *Based on 10 patients.
BMI, body mass index; HD, haemodialysis; N/A: not applicable.
Table 1. Baseline characteristics of patients and 
healthy subjects
Fig. 1 Trial design. All subjects had eight visits to 
the trial centre, seven daily doses of rhGH and a 
follow-up visit (Days 16–19). Patients had an 
additional assessment visit on Days 8–9, received 
an additional rhGH dose on Day 8 and had four 
dialysis sessions over the 9-day period. 
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Patients with ESRD received haemodialysis treatment on alternate
days three times during the study, and had an additional assessment
visit (Days 8–9), which included a dialysis session. The ﬁrst dose of
rhGH (Norditropin® SimpleXx®, Novo Nordisk A/S, Bagsvaerd,
Denmark) was administered in the evening of Day 1 and daily dosing
continued up to Day 7. Patients received an additional dose on Day 8
in order to record the GH exposure during dialysis. All subjects received
a dose of 50 
 
μ
 
g/kg body weight (bw)/day (maximum 4 mg/day) by
subcutaneous injection. In case of unacceptable side effects the dose
was to be lowered by 25% to 38 
 
μ
 
g/kg/day for the rest of the study.
 
Measurements
 
The GH exposure of each subject was recorded at baseline and on
Days 7–8 (also on Days 8–9 for patients only) by measuring GH con-
centration every 30 min (± 10 min) for 24 h, starting immediately
after dosing at 20·00 h. GH exposure was determined as the AUC
from the 24-h GH proﬁle. The primary end-point was the GH
exposure at steady-state (AUC
 
0–24 h
 
) on Days 7–8. Determination of
GH in serum samples was performed using an enzyme-linked
immunosorbentassay (ELISA) method [kit 10–1900; Diagnostic
Systems Laboratories (DSL) Inc, Webster, TX] with an intra- and
interassay coefﬁcient of variation (CV) of 4·0% and 6·5%,
respectively. AUC
 
0–24 h
 
 was calculated by the trapezoidal rule.
Secondary efﬁcacy variables included PK and PD assessments.
Fasting blood samples for analysis of PD variables in serum at screen-
ing and Day 8 were taken after an overnight fast. ELISA methods
were used for all analyses (IGF-I: kit 10–5600, intra- and interassay
CV 6·0% and 6·7%, respectively; IGFBP-I: kit 10–7800, intra- and
interassay CV 2·9% and 6·9%, respectively; IGFBP-III: kit 10–6600,
intra- and interassay CV 8·8% and 10·0%, respectively; GHBP: kit
10–48100, intra- and interassay CV 4·5% and 6·6%, respectively; kits
all supplied by DSL Inc). The molar ratio for IGF-I/IGFBP-III was
also calculated using the following equation:
(IGF-I/7·5)/(IGFBP-III/30·5)
The safety assessments included routine haematology and clinical
chemistry, measured at baseline and on Day 8, and adverse events
(AE), which were monitored daily during the study.
 
Statistical analysis
 
The primary analysis was based on a 90% CI of the ratio (patients :
healthy subjects) of the AUC
 
0–24 h
 
 of GH at steady-state (Days 7–8).
With 10 subjects per group, a statistical power of more than 80%
was obtained, enabling us to claim that the 90% CI lies embedded
in the interval 67–150%. This interval was considered to be sufﬁ-
ciently narrow to allow us to evaluate whether or not renal disease
had a clinically signiﬁcant effect. The statistical power calculation
was made based on the hypothesis that there was no difference
between the mean AUC
 
0–24 h
 
 in the two populations and a CV for
AUC
 
0–24 h
 
 of 30% (data on ﬁle, Novo Nordisk
 
29
 
).
All subjects carried out trial procedures according to the protocol
and were included in the primary analysis. For the primary analysis,
a linear normal model (
 
ancova
 
) for the logarithmically transformed
values of AUC
 
0–24 h
 
 was used. The model included effects of subject
group, daily dose/kg bw, and gender. From the model, the difference
in means of the log-transformed values was estimated together with
90% CI and these estimates were then exponentially transformed
in order to obtain estimates of the patients : healthy subjects ratio
and 90% CI.
Secondary PK end-points AUC
 
0–12 h
 
, AUC
 
18–24 h
 
, AUC
 
0–
 
∞
 
, and C
 
max
 
at steady-state were analysed as described for the primary end-point,
as were total body clearance (Cl/f) and 
 
t
 
1/2,z
 
, except that these
end-points were considered to be dose-independent, thus the dose
factor was omitted from the models. Time to reach maximum GH
concentration (
 
t
 
max
 
) was analysed using the nonparametric Kruskal–
Wallis test based on Wilcoxon scores and the median difference
between the two subgroups was estimated together with a 90% CI
using the Hodges–Lehmann estimator.
Analysis of the PD end-points IGF-I and IGFBP-III was performed
on the standard deviation score values, including an adjustment for
gender. The following formula was used to calculate the SD score
values:
SD score = 
 
X
 
 – [(
 
H
 
 + 
 
L
 
)/2]/(
 
H
 
 – 
 
L
 
)/4
where 
 
X
 
 corresponds to the biomarker and 
 
L
 
 and 
 
H
 
 are the respective
low and high laboratory references (DSL Inc). Change from baseline
to steady-state for all PD end-points was analysed between subject
groups by an 
 
ancova
 
, including subject group as ﬁxed effect and the
baseline assessment as covariate.
No statistical analyses were performed on the safety end-points.
The Statistical Analysis System software package (version 8·2; SAS
Institute, Cary, NC) was used to analyse results. A 
 
P
 
-value < 0·05 was
taken to indicate signiﬁcance and all statistical tests were two-sided.
 
Results
 
Trial subjects were recruited between June and November 2005. Of
the 21 subjects allocated to treatment, a total of 20 (10 patients and
10 healthy subjects) completed the trial. One patient was withdrawn
by the sponsor on Day 8 due to a shunt obstruction (evaluated as
unlikely to be related to trial product by both investigator and
sponsor), but was included in the primary outcome analysis on Days
7–8. There were two protocol deviations affecting six subjects: the
follow-up visit for the withdrawn patient was performed later than
planned and venous sampling for ﬁve subjects began later than
20·10 h (planned 20·00 h ± 10 min) for some visits. These were
considered not to have had any bearing on the trial results.
At baseline, IGFBP-I and IGFBP-III values were signiﬁcantly
higher in patients compared with healthy subjects at baseline
(Table 2), whereas GHBP values in healthy subjects at baseline were
almost double those in patients (
 
P = 
 
0·01). There was no signiﬁcant
difference in IGF-I values or IGF-I/IGFBP-III molar ratio between
patients and healthy subjects.
 
Primary end-point
 
The geometric mean GH AUC
 
0–24 h
 
 at steady-state (Days 7–8) was
two-thirds greater for patients than for healthy subjects (Table 3). 
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A difference between patients and healthy subjects was indicated
by the fact that the 90% CI for the estimated patient : healthy
subject ratio did not fall within the acceptance interval (0·67–
1·50).
 
Secondary PK end-points
 
The GH AUC
 
0–12 h
 
 geometric mean at steady-state for patients was
almost double that for healthy subjects (Table 3). Based on the 90%
CI, a difference between patients and healthy subjects was indicated
for this and all other secondary PK end-points. The geometric mean
GH AUC
 
18–24 h
 
 at steady-state for healthy subjects was double that
for patients. Individual/mean GH proﬁles on Days 7–8 are shown
in Fig. 2. Of particular note is the fact that GH concentrations for
both patients and healthy subjects were comparable with baseline
values by about 20–22 h, demonstrating that administered rhGH
does not seem to be retained in the circulation of patients with ESRD.
Moreover, the geometric mean GH AUC
 
18–24 h
 
 steady-state for both
patients and healthy subjects (Table 3) was about the same as the
baseline mean values (Table 2). Individual GH proﬁles (not shown)
for the period 18–24 h on Days 7–8 were relatively ﬂat compared to
the peaks obtained on Day 1 for all subjects (particularly noticeable
for the patient group) (Fig.  2, inserts), demonstrating that
administration of rhGH appeared to suppress endogenous GH
production.
The geometric mean GH AUC
 
0–
 
∞
 
 steady-state for patients was
two-thirds greater than that for healthy subjects. The C
 
max
 
 geometric
mean for patients at steady-state was double that for healthy subjects.
With regard to 
 
t
 
max
 
, the median values for patients and healthy
subjects were approximately the same and no signiﬁcant difference
was found between patients and healthy subjects (
 
P = 
 
0·8). Individual
GH proﬁles (Fig. 2) also demonstrated the higher GH concentration
(C
 
max
 
 and AUC
 
0–24 h
 
) measured for patients compared to healthy
subjects, and also that 
 
t
 
max
 
 for both groups was reached in 4–5 h
(range 3–9 h) after dosing.
The geometric mean of Cl/f at steady-state for healthy subjects was
two-thirds greater than that for patients. Similarly, the geometric
mean of 
 
t
 
1/2,z
 
 for healthy subjects was greater (1·4 times) than that
for patients.
In patients only, GH variables on Days 7–8 were compared
with the same period on Days 8–9, which included a dialysis
session (data not shown). There appeared to be no difference
between values on Days 7–8 and Days 8–9 for any secondary PK
end-point, except for AUC
 
18–24 h
 
 and 
 
t
 
max 
 
(Days 7–8 mean values were
greater than Days 8–9 values) and C
 
max 
 
(Days 8–9 values were
greater).
Table 2. Baseline endocrine parameters in the patients and healthy subjects
Variable Patients (N = 11) Healthy subjects (N = 10) P-value (95% CI)
PTH (pmol/l) 39·9 ± 34·0 (4·0–109·1) 3·8 ± 1·1 (2·4–6·1) ND
AUC18–24 h (μg h/l) 2·86 ± 3·91 1·09 ± 1·43 ND
IGF-I SD score –0·6 ± 0·9 (–1·7–0·9) –1·0 ± 0·9 (–1·8–1·1) 0·32 (–0·42; 1·24)
IGF-I (ng/ml) 210 ± 76 (117–322) 178 ± 76 (111–362) 0·30 (0·85; 1·66)
IGFBP-I (ng/ml) 67·4 ± 42·3 (6·3–126·3) 26·8 ± 28·3 (6·4–85·4) 0·03 (1·08; 6·19)
IGFBP-III SD score 2·2 ± 1·5 (–0·6–4·7) 0·4 ± 0·8 (–1·3–1·5) 0·004 (0·63; 2·90)
IGFBP-III (ng/ml) 5025 ± 1038 (3067–6654) 3708 ± 367 (3208–4211) 0·002 (1·13; 1·57)
GHBP (pmol/l) 993 ± 610 (186–1972) 1743 ± 512 (1134–2586) 0·01 (0·27; 0·82)
IGF-I/IGFBP-III molar ratio 0·2 ± 0 (0·1–0·2) 0·2 ± 0·1 (0·1–0·4) 0·37 (0·68; 1·16)
Values are the mean ± SD (range), except for AUC18–24 h (mean ± SD).
PTH, parathyroid hormone; ND, not done; IGF-, insulin-like growth factor-; IGFBP-, insulin-like growth factor binding protein-; SD, standard deviation.
Table 3. Primary and secondary pharmacokinetic (PK) efﬁcacy endpoints at steady-state (Days 7–8)
Variable Patients (N = 11) Healthy subjects (N = 10) Patients : healthy subjects ratio 90% CI
AUC0–24 h (μg h/l)* 387·91 ± 134·13 225·35 ± 59·63 1·71 1·40; 2·07
AUC0–12 h (μg h/l) 360·16 ± 134·04 194·00 ± 57·42 1·84 1·49; 2·26
AUC18–24 h (μg h/l) 3·03 ± 2·71 6·37 ± 4·21 0·48 0·26; 0·88
AUC0–8 (μg h/l) 388·90 ± 134·07 228·53 ± 60·45 1·69 1·39; 2·05
Cmax (μg/l) 55·15 ± 26·87 27·29 ± 10·90 1·99 1·53; 2·59
tmax (h) 5·00 (3·00; 6·50) 4·50 (3·50; 9·00) N/A –1·0; 1·0
Cl/f (l/h) 9·64 ± 3·61 16·45 ± 6·11 0·59 0·45; 0·76
t1/2,z (h)† 2·28 ± 0·43 3·23 ± 0·75 0·71 0·60; 0·83
Values are the geometric mean ± SD, except for tmax [median (minimum; maximum)].
*Primary end-point; †Terminal half-life; N/A, not applicable. 
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Secondary PD end-points
The mean PD data showing change from baseline to steady-state
are presented in Table 4. Only IGFBP-III and associated SD score
showed a signiﬁcant difference (P = 0·001) between patients and
healthy subjects. IGF-I SD score, and to a lesser extent IGFBP-III
SD score, increased in both groups compared with baseline,
whereas GHBP, and to a lesser extent IGFBP-I, decreased. The
IGF-I/IGFBP-III molar ratio increased slightly for both groups,
but there was no signiﬁcant difference between groups. It should
be noted that data for all biomarkers, except IGFBP-III, were
highly variable, as depicted in the SDs, particularly in the patient
group.
There was no signiﬁcant difference in any of the PD biomarker
values on Days 7–8 compared with Days 8–9 in ESRD patients (data
not shown).
Safety
No major safety issues were identiﬁed during the trial. The most
common adverse events were headaches (13 events, reported equally
between patients and healthy subjects) and peripheral oedemas (six
events, all but one in healthy subjects). During the trial, two subjects
had the rhGH dose reduced. One patient experienced a severe
adverse event (vomiting), which lasted a day and one healthy subject
had a headache that lasted for 8 days. These events were considered
probably related to trial product and the dose of rhGH was reduced
on Day 7 and Day 5, respectively.
Discussion
In this study, treatment with GH did result in higher exposure
in patients with ESRD than in healthy subjects on Days 7–8, as
Fig. 2 Individual (narrow lines) and mean (thick 
lines) GH proﬁles for patients (top) and healthy 
subjects (bottom) on Days 7–8. Inserts show 
individual proﬁles on Day 1.Growth hormone and haemodialysis patients 781
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demonstrated by the markedly greater AUC0–24 h (primary end-point),
AUC0–12 h and Cmax. However, as the individual subjects proﬁles
were back to baseline by 20–22 h, it is concluded that no overall
accumulation of GH occurs. Results of this study were in agreement
with previous studies which showed a greater AUC
25 and a reduced
metabolic clearance rate
23–25 in patients with chronic renal failure
compared with in healthy controls, following intravenous
administration of GH. The fractional clearance rate Cl/f in our study
was also lower in ESRD patients than in healthy subjects. Taken
together, results demonstrate an impaired clearance of GH in
patients with ESRD, supporting that the kidney plays an important
role in GH elimination.
23–25
In the current study, the terminal half-life t1/2,z was shorter for
patients compared with for healthy subjects, resulting in AUC18–24 h
for ESRD patients being lower than for healthy subjects. This,
combined with the fact that GH concentrations 20–22 h after dosing
on Day 8 were similar to baseline values for both groups, indicates
that GH did not remain in the circulation of ESRD patients longer
than in healthy individuals, as had been considered a possibility at
the outset of the study.
23,25,26 Moreover, the return to baseline values
for both treatment groups suggested that the difference in AUC18–24 h
between groups was likely to be of no clinical signiﬁcance.
The metabolic half-life of GH has been reported to vary between
about 7–50 min in healthy subjects, and it is signiﬁcantly longer in
patients with chronic renal failure.
23–25 In this study, on the other
hand, t1/2,z for healthy individuals was 03·23 h, in agreement with the
2–4 h observed in previous studies of the PK of subcutaneous GH
administration in healthy males.
30,31 PK parameters for GH have
been shown to vary depending on whether the administration
method used is transcutaneous or subcutaneous, and it has been
demonstrated that GH kinetics after subcutaneous administration
have a ‘ﬂip-ﬂop’ characteristic, whereby the absorption rate
approximates the rate of elimination.
32 Results of our study support
that conclusion. Patients with ESRD had a shorter t1/2,z of 02·28 h,
reﬂecting an apparent higher absorption rate for patients compared
with healthy volunteers. The higher AUC0–24 h in patients compared
with in healthy subjects therefore may be explained by a lower overall
clearance, whereas the higher Cmax may be explained by a combination
of the lower clearance and a faster absorption (suggested by the
faster terminal slope). Additionally, the lower AUC18–24 h for ESRD
patients partly reﬂects a faster absorption compared with in healthy
individuals.
The wide variation in the GH half-lives reported in the literature
has been explained by the use of different methodologies, and inter-
ference by the secretion of endogenous GH.
23,25 A limitation of the
current study therefore is that endogenous GH secretion was not
suppressed. Nevertheless, our results were in agreement with other
studies, and the fact that individual GH proﬁles at 18–24 h on Days
7–8 were relatively ﬂat compared to those obtained on Day 1 suggests
that GH administration did suppress endogenous GH production
to some extent.
The reduced clearance observed for ESRD patients in the current
study (58% of that for healthy individuals) is in agreement with
other studies which have demonstrated a reduction in the metabolic
clearance rate (MCR) of GH of about 50% for patients with chronic
renal failure, and commensurate with a GH plasma half-life double
that of healthy controls.
23–25 GH appears to be eliminated in humans
by a biocompartmental model,
25,33 with unbound GH in a central
compartment and GHBPs and bound GH in a peripheral compart-
ment. In healthy individuals, the kidney accounts for about 50% of
the total MCR,
23 and it is less than this in patients with renal disease,
24
whereas extrarenal elimination (mostly via the liver) does not seem
to differ signiﬁcantly between the two groups.
23 However, the situation
is made more complex by the fact that GH also exists (reversibly)
bound to GHBP, which is decreased in ESRD patients; the relative
amounts of bound GH will most likely also correlate with the GH
elimination rate.
No major safety concerns were raised with this trial. The high
mean Cmax (double that for healthy controls) and greater AUC0–24 h
observed for patients with ESRD might be considered to have the
potential to adversely inﬂuence the safety proﬁle of rhGH. However,
this seems not to be the case as GH appeared to be well tolerated
generally and no differences in the safety proﬁles between the two
groups were observed. The most common adverse events were
headache and peripheral oedema, but these were not unexpected and
neither occurred with greater incidence in the ESRD patient group.
It is known that short-term rhGH administration can lead to ﬂuid
retention.
34 In this trial, most events of oedema occurred in healthy
subjects, probably because body ﬂuid control is strictly regulated
during dialysis treatment. One patient and one healthy subject had
a GH dose reduction. The rhGH dose chosen was the highest dose
employed in a previous trial of subcutaneous GH treatment in 139
patients with ESRD (37 dosed with 50 μg/kg bw/day, as in this trial),
where GH treatment was found to be safe.
21
Table 4. Secondary pharmacodynamic (PD) efﬁcacy end-points at steady-state (Days 7–8), change from baseline
Variable, change from baseline Patients (N = 11) Healthy subjects (N = 10) Patients – healthy subjects difference P-value (95% CI)
IGF-I SD score 9·3 ± 4·5 7·7 ± 1·5 0·84 0·55 (–2·08; 3·76)
IGF-I (ng/ml) 756 ± 361 630 ± 98 74·4 0·51 (–159; 308)
IGFBP-I (ng/ml) –31·6 ± 39·6 –18·7 ± 27·8 12·7 0·36 (–15·6; 41·0)
IGFBP-III SD score 3·4 ± 0·6 2·2 ± 0·5 1·22 0·001 (0·58; 1·86)
IGFBP-III (ng/ml) 2615 ± 467 1693 ± 370 1029 0·001 (505; 1553)
GHBP (pmol/l) –74·1 ± 167·2 –195 ± 134·9 69·6 0·40 (–100; 239)
IGF-I/IGFBP-III molar ratio 0·3 ± 0·2 0·4 ± 0·0 –0·07 0·20 (–0·18; 0·04)
Values are the mean ± SD. IGF-, insulin-like growth factor-; IGFBP-, insulin-like growth factor binding protein-; SD, standard deviation.782 I. H. Langbakke et al.
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With respect to standard GH biomarkers at steady-state, only
IGFBP-III showed a signiﬁcant difference between patients and
healthy subjects after GH treatment and was greater for patients.
Patients with ESRD are often resistant to GH and have a diminished
rate of secretion of IGF-I.
12 In concordance with previous trials, this
study demonstrated an increase in IGF-I and IGF-I SD score in
patients with ESRD after treatment with GH.
13,15–17,20 There was a
similar increase in healthy subjects, and no signiﬁcant difference
between the two groups was observed.
13,15,16,20 Concerns have been
raised regarding the potential risk of cancer associated with increased
IGF-I as a result of GH exposure, and the molar ratio of IGF-I and
IGFBP-III may be important in determining the relative risk of
malignancy.
35 In the current study, although IGFBP-III was signiﬁ-
cantly greater for patients compared with healthy subjects, as has
been observed previously during GH treatment of patients receiving
haemodialysis,
22 both IGF-I and the IGF-I/IGFBP-III molar ratio
increased for both patients and healthy subjects, as was also reported
previously,
14,15 and there was no signiﬁcant difference between groups.
A possible role for IGF-I monitoring has been suggested to avoid
morbidities associated with IGF-I excess, as well as deﬁciency.
35 It
should be noted that size-exclusion chromatography (to exclude
any immunoreactive fragments of IGFBP-III formed as a result of
IGFBP-III protease activity) was not performed in this study; there-
fore, concentrations of IGFBP-III may have been overestimated.
In agreement with previous reports,
23,36,37 the baseline con-
centrations of IGFBP-III and IGFBP-III SD score were signiﬁcantly
elevated in patients with ESRD. IGFBP-I was also signiﬁcantly greater
in ESRD patients at baseline, as has been previously reported,
13
whereas baseline GHBP was signiﬁcantly reduced. Previous inves-
tigations of patients with chronic renal failure have also observed
reduced concentration of GHBP,
24,38 which may indicate decreased
expression of the GH receptor in target tissues, and hence diminished
responsiveness to GH in renal failure. The lower concentrations of
GHBP may also have contributed to the observed reduction in
plasma clearance (and hence increase in AUC) in the ESRD patients
compared with healthy subjects. A PK study of intravenous GH
administration found a strong positive correlation between baseline
GHBP concentration and MCR at physiological GH concentrations.
39
In addition, the reduced GH elimination rate observed in GH-
deﬁcient patients in another study was explained by lower levels of
GHBP, possibly reﬂecting a reduced GH receptor density and hence
clearance.
40
In contrast to a study of patients with chronic renal failure
undergoing dialysis,
13 baseline IGF-I was not signiﬁcantly higher
in patients compared with healthy controls in the present study.
In general, patients with ESRD appear to exhibit normal or high
concentrations of IGF-I and considerably elevated concentrations
of IGFBP-I and IGFBP-III, which increase with declining renal
function,
13 demonstrating that the GH–IGF-I axis is affected on
several levels.
There was no marked effect of dialysis on GH PK and PD
parameters, assessed in patients only on Days 8–9. The differences
observed in AUC18–24 h, tmax and Cmax between steady-state and dialysis
were judged to be of no clinical signiﬁcance.
To date, a number of trials have demonstrated a beneﬁt of GH
treatment in patients with ESRD. Major adverse events have not been
reported and GH does not appear to accumulate in the circulation
of ESRD patients. However, further trials are needed to assess the
ultimate effects of GH treatment on morbidity and mortality.
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